ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 11, 2020 16:30 JST
Source:
Synergy Pharmaceuticals
Novel approach from Synergy Pharmaceuticals may hold cure to herpes virus
Sydney, Aus, Feb 11, 2020 - (ACN Newswire) - There is an immediate need for alternative treatments to combat the spread of Herpes type 1 & 2 strains. The United States alone reports over 750,000 new cases of herpes infections every year. Alarming figures especially when coupled with the increased risk for pregnant women, newborn babies and with the incidence of herpes encephalitis on the rise. Existing options include antivirals that have been approved for clinical administration and a limited number of nucleoside analogues.
A recent study by Synergy Pharmaceuticals (www.synergy-pharmaceuticals.com) in association with ACU may set a new stream of thought on the topic by bringing back traditional medicine as an opportunity to make a difference. Their study served to investigate a relatively novel approach to breaking down the herpes viral envelope by employing specific T Cells generated through a particular Amino Acid formula.
The treatment consisted of five immunotherapeutic core compounds (5CC) comprising of Rhodiola, Tribulus, Astragalus, Lysine and a proprietary Amino Acid Formula. These 5CC are effective inhibitors of herpes viral DNA synthesis and interferon (IFN)-induced cellular antiviral response and were found to neutralize antiviral reproduction by blocking cell-to-cell infection.
The aim of this study was to explore alternative substitutes to treat herpes simplex virus infection and prevent viral reproduction where conventional medications had previously failed. Testing was performed using 5CC with immunotherapeutic features to be able to neutralize herpes viral activity inside the human body. For the first time, this study highlighted the combinations capacity to act by preventing cell-to-cell infection to suppress the activity of the virus.
The study also focused on the immune-inhibiting properties of the 5CC which indicated cell membrane breakdown and eradication. A randomized, investigator-blinded method was performed on patients with a moderate to high positive concentration of herpes serum antibodies. A longitudinal approach was adopted over 6 months, where participants' infection rates were measured at various points during the treatment. Antiviral activity of the 5CC against HSV-1 and HSV-2 was tested on RC-37 cells in vitro using a plaque reduction assay.
The study was able to validate that for some participants there was a noted progression from a positive antibody serology to a negative one. This was the first time evidence has documented a cure for the herpes simplex virus.
This research shows considerable scope, particularly in the natural approach to viral infection treatment options, while it is the first study that has documented herpes serum antibody results that confirmed a positive to negative transition for participants. The results validated the earlier aims that 5CC provides far greater elimination in viral cell breakdown than any other conventional antiviral medication or vaccine thus far. Indicators of the 5CC found that the combination exhibited high levels of virucidal activity against HSV-1 and HSV-2 in viral suspension. These results suggest that the 5CC are strong alternative candidates for treating herpes simplex.
Follow up investigations have demonstrated further promising results, still utilising the same 5CC from the study. In light of this research and the current demands for a more natural approach, Synergy has seen expansion across the Australian, American and Asian markets. Further avenues into Europe appear to be stagnant however due to limitations on the accessibility of imported natural medicine, a situation which may serve to highlight the drastic shortcomings in the over-regulation of health and supplements.
While this appears to be the first and only successful cure for the herpes virus the researchers went on to reflect; there is however, no immunity for sufferers once clear of the herpes virus, potentially leaving the door open to reinfection later if the individual is not careful. This study though may well pave the way for a departure from the standard antiviral pharmaceutical mentality, which has dominated medical profession culture on the treatment options for viral disease for so many years.
Synergy Pharmaceuticals
Simon Anderson
info@synergy-pharmaceuticals.com
www.synergy-pharmaceuticals.com
1. CDC. (January 31, 2017). Genital Herpes - CDC Fact Sheet (Detailed). Reference:
https://www.cdc.gov/std/herpes/stdfact-herpes-detailed.htm
2. American Sexual Health Association. (April 18, 2019). Herpes treatment. Reference:
http://www.ashasexualhealth.org/stdsstis/herpes/herpes-treatment/
3. May, Brandon. (July 10, 2018). Abandoned Genital Herpes Vaccine GEN-003 Found to Reduce Lesions, Decrease Viral Shedding at Varying Doses. Reference:
https://bit.ly/3bsG2I2
4. Taylor, Marisa. (April 12, 2018). FDA Launches Criminal Investigation Into Unauthorized Herpes Vaccine Research. Reference:
https://bit.ly/38iO9VE
5. Raymond, Nate. (December 7, 2018). Genocea Biosciences ducks investor lawsuit over herpes vaccine. Reference:
https://reut.rs/2uExGwz
6. Sciforum Journals. (December 20, 2019). Isolation and elimination of Latent and Productive Herpes Simplex Virus from the Sacral and Trigeminal Ganglions. Reference:
https://viruses2020.sciforum.net
7. Berman, Robby. (November 23, 2019). How dormant herpes springs back to life. Reference:
https://www.medicalnewstoday.com/articles/327105.php#2
Source: Synergy Pharmaceuticals
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>